David P. Curley

5.0k total citations · 2 hit papers
24 papers, 3.5k citations indexed

About

David P. Curley is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, David P. Curley has authored 24 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Hematology and 6 papers in Oncology. Recurrent topics in David P. Curley's work include Acute Myeloid Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). David P. Curley is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). David P. Curley collaborates with scholars based in United States, Canada and Switzerland. David P. Curley's co-authors include Marcus Bosenberg, Martin McMahon, David Dankort, Ifor R. Williams, Betsy Nelson, William Damsky, Ronald A. DePinho, M. James You, Anthony N. Karnezis and D. Gary Gilliland and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Genetics and Blood.

In The Last Decade

David P. Curley

24 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BrafV600E cooperates with Pten loss to induce metastatic melanoma

2009 835 citations David Dankort, David P. Curley et al. Nature Genetics profile →
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors

2004 513 citations Brian J.P. Huntly, Hirokazu Shigematsu et al. Cancer Cell profile →

Peers

David P. Curley

HEMAT

ONCOL

IMMUN

GENET

Paul Coughlin Australia

Reinhold Munker United States

Markus Y. Mapara United States

Bertil Glader United States

Talal Al Saati France

John M. Ashton United States

William F. C. Rigby United States

Ingo Tamm Germany

Harald Burkhardt Germany

David B. Sykes United States

Paul Coughlin Australia

David P. Curley

965 ×0.4

726 ×0.7

HEMAT

342 ×0.4

ONCOL

530 ×0.9

IMMUN

295 ×0.7

GENET

Citations per year, relative to David P. Curley David P. Curley (= 1×) peers Paul Coughlin

Countries citing papers authored by David P. Curley

Since Specialization

Citations

This map shows the geographic impact of David P. Curley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David P. Curley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David P. Curley more than expected).

Fields of papers citing papers by David P. Curley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David P. Curley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David P. Curley. The network helps show where David P. Curley may publish in the future.

Co-authorship network of co-authors of David P. Curley

This figure shows the co-authorship network connecting the top 25 collaborators of David P. Curley. A scholar is included among the top collaborators of David P. Curley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David P. Curley. David P. Curley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Papanagnou, Dimitrios, et al.. (2018). Neurosyphilis: A Simulation Case for Emergency Medicine Residents. Cureus. 10(7). e2984–e2984. 2 indexed citations

Zhang, Xiao Chi, et al.. (2018). Man with a Swollen Eye: Nonspecific Orbital Inflammation in an Adult in the Emergency Department. Journal of Emergency Medicine. 55(1). 110–113. 6 indexed citations

Murphy, Kiera, David P. Curley, Tom F. O’Callaghan, et al.. (2017). The Composition of Human Milk and Infant Faecal Microbiota Over the First Three Months of Life: A Pilot Study. Scientific Reports. 7(1). 40597–40597. 275 indexed citations

Damsky, William, Goran Micevic, Katrina Meeth, et al.. (2015). mTORC1 Activation Blocks BrafV600E-Induced Growth Arrest but Is Insufficient for Melanoma Formation. Cancer Cell. 27(1). 41–56. 87 indexed citations

Venkatesh, Arjun K., David P. Curley, Yuchiao Chang, & Shan W. Liu. (2015). Communication of Vital Signs at Emergency Department Handoff: Opportunities for Improvement. Annals of Emergency Medicine. 66(2). 125–130. 40 indexed citations

Slutzman, Jonathan E., David P. Curley, Wendy Macias‐Konstantopoulos, & David F.M. Brown. (2015). Altered Mental Status and Tachycardia. Journal of Emergency Medicine. 48(5). 597–602. 2 indexed citations

Sri‐on, Jiraporn, Yuchiao Chang, David P. Curley, et al.. (2014). Boarding is associated with higher rates of medication delays and adverse events but fewer laboratory-related delays. The American Journal of Emergency Medicine. 32(9). 1033–1036. 39 indexed citations

Alvarez, Vincent, M. Brandon Westover, Frank W. Drislane, et al.. (2014). Evaluation of a clinical tool for early etiology identification in status epilepticus. Epilepsia. 55(12). 2059–2068. 27 indexed citations

Damsky, William, David P. Curley, Manjula Santhanakrishnan, et al.. (2011). β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell. 20(6). 741–754. 267 indexed citations

10.

Held, Matthew A., David P. Curley, David Dankort, et al.. (2010). Characterization of Melanoma Cells Capable of Propagating Tumors from a Single Cell. Cancer Research. 70(1). 388–397. 73 indexed citations

11.

Dankort, David, David P. Curley, Betsy Nelson, et al.. (2009). BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nature Genetics. 41(5). 544–552. 835 indexed citations breakdown →

12.

Yang, Guang, David P. Curley, Marcus Bosenberg, & Hensin Tsao. (2007). Loss of Xeroderma Pigmentosum C ( Xpc ) Enhances Melanoma Photocarcinogenesis in Ink4a-Arf –Deficient Mice. Cancer Research. 67(12). 5649–5657. 34 indexed citations

13.

Muthusamy, Viswanathan, Sekhar Duraisamy, C. Matthew Bradbury, et al.. (2006). Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma. Cancer Research. 66(23). 11187–11193. 137 indexed citations

14.

Bosenberg, Marcus, Viswanathan Muthusamy, David P. Curley, et al.. (2006). Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice. genesis. 44(5). 262–267. 117 indexed citations

15.

Lee, Benjamin H., Ifor R. Williams, Ema Anastasiadou, et al.. (2005). FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene. 24(53). 7882–7892. 60 indexed citations

16.

Growney, Joseph D., Hirokazu Shigematsu, Zhe Li, et al.. (2005). Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 106(2). 494–504. 364 indexed citations

17.

Huntly, Brian J.P., Hirokazu Shigematsu, Kenji Deguchi, et al.. (2004). MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 6(6). 587–596. 513 indexed citations breakdown →

18.

Growney, Joseph D., Hirokazu Shigematsu, Zhe Li, et al.. (2004). Loss of Runx1 Perturbs Adult Hematopoiesis and Is Associated with a Myeloproliferative Phenotype.. Blood. 104(11). 227–227. 9 indexed citations

19.

Kelly, Louise, Jin‐Chen Yu, Christina Boulton, et al.. (2002). CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 1(5). 421–432. 240 indexed citations

20.

Kelly, Louise, Jeffrey L. Kutok, Ifor R. Williams, et al.. (2002). PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proceedings of the National Academy of Sciences. 99(12). 8283–8288. 236 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact